While we applaud the Minnesota Department of Health for rejecting several proposed uses for medical marijuana, we also question the department's decision to add Alzheimer's disease to the list of conditions approved for such treatment.
A Star Tribune story ("Rx for Alzheimer's: Pot," Dec. 4) notes that the Health Department declined to approve six conditions, including opioid use disorder, which we argued against in public comments. The evidence just doesn't exist to support the use of marijuana to treat opioid use disorder; in fact, the evidence points to significant risks for some patients. Leaving that condition off the medical marijuana list was a good decision.
Approving Alzheimer's, on the other hand, seems premature, and not without risk.
For readers wondering how an intoxicant like marijuana could help with memory, they're not alone. Even the national Alzheimer's Association is opposed to the idea. Why? Because the data supporting it is not robust.
Some of the research is promising, to be sure. But the eagerness to approve medical marijuana on hopeful signs, rather than after rigorous scientific scrutiny and approval from the U.S. Food and Drug Administration, reflects a disregard for the risks associated with marijuana use. Those risks are a bit lower in Minnesota, thanks to the state limiting medical marijuana to non-smokable forms (e.g., pills and liquids), but they are risks nonetheless, and well-documented risks — including the risk of memory loss.
Even if the train has left the station on marijuana, we ought to slow it down and step up research and regulatory efforts nationally before getting further down the tracks.
Marvin D. Seppala, M.D., Center City, Minn.
The writer is the chief medical officer of the Hazelden Betty Ford Foundation in Center City, Minn.
Business
In handling aftermath of fraud, CHS executive shows leadership
CHS Inc. had a problem. One of its employees misstated rail freight contracts. There was fraud and it affected the company's profits (" 'No excuse,' CEO says as CHS lowers profit," Dec. 4). Yet Chief Executive Jay Debertin doesn't blame or rail against anyone. He actually takes ownership of the problem: "We had a lack of controls … and there's no excuse for that, and we own that and I own that. … I'm not going to look for some clever way of downplaying it and making it look better than it was."